Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study

References

• Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261–283.
   Google Scholar
• European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
   PubMed Web of Science ®Google Scholar
• Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58:879–885; quiz 886–878.
   PubMed Web of Science ®Google Scholar
• Tuthill C, Rios I, McBeath R. Thymosin alpha 1: past clinical experience and future promise. Ann N Y Acad Sci. 2010;1194:130–135.
   PubMed Web of Science ®Google Scholar
• Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385–1396.
   PubMed Web of Science ®Google Scholar
• Dirchwolf M, Podhorzer A, Marino M, et al. Immune dysfunction in cirrhosis: distinct cytokines phenotypes according to cirrhosis severity. Cytokine. 2016;77:14–25.
   PubMed Web of Science ®Google Scholar
• Marquez M, Fernandez-Gutierrez C, Montes-de-Oca M, et al. Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis. Clin Exp Immunol. 2009;158:219–229.
   PubMed Web of Science ®Google Scholar
• Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9:593–608.
   PubMed Web of Science ®Google Scholar
• Sugahara S, Ichida T, Yamagiwa S, et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol Res. 2002;24:346–354.
   PubMed Web of Science ®Google Scholar
• Chan HL, Tang JL, Tam W, et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther. 2001;15:1899–1905.
   PubMed Web of Science ®Google Scholar
• Yang Y-F, Zhao W, Zhong Y-D, et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res. 2008;77:136–141.
   PubMed Web of Science ®Google Scholar
• Kim BH, Lee Y-J, Kim W, et al. Efficacy of thymosin alpha-1 plus peginterferon alpha-2a combination therapy compared with peginterferon alpha-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. Scand J Gastroenterol. 2012;47:1048–1055.
   PubMed Web of Science ®Google Scholar
• Lim SG, Wai C-T, Lee YM, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11:245–253.
   PubMed Web of Science ®Google Scholar
• Zhang YY, Chen EQ, Yang J, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J. 2009;6:63.
   PubMedGoogle Scholar
• Naylor PH, Mutchnick MG. Immunotherapy for hepatitis B in the direct acting antiviral era: reevaluating the thymosin alpha1 efficacy trials in the light of a combination therapy approach. J Viral Hepat. 2018;25:4–9.
   PubMed Web of Science ®Google Scholar
• Giacomini E, Severa M, Cruciani M, et al. Dual effect of Thymosin alpha 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists. Expert Opin Biol Ther. 2015;15(Suppl 1):S59–S70.
   PubMedGoogle Scholar
• Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339–345.
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhou J, Wang L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017;65:1438–1450.
   PubMed Web of Science ®Google Scholar
• Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why? Liver Int. 2015;35(Suppl 1):78–81.
   PubMedGoogle Scholar
• Rockey DC. Liver fibrosis reversion after suppression of hepatitis B virus. Clin Liver Dis. 2016;20:667–679.
   PubMed Web of Science ®Google Scholar
• Lee HW, Lee JI, Um SH, et al. Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. J Gastroenterol Hepatol. 2008;23:729–735.
   PubMed Web of Science ®Google Scholar
• Qiu SJ, Zhou ZG, Shen F, et al. A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection – first announcement of the protocol. Expert Opin Biol Ther. 2015;15(Suppl 1):S133–S137.
   PubMedGoogle Scholar
• Garaci E, Pica F, Rasi G, et al. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol. 2000;22:1067–1076.
   PubMed Web of Science ®Google Scholar
• Shuqun C, Mengchao W, Han C, et al. Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology. 2004;51:1445–1447.
   PubMedGoogle Scholar
• Shuqun C, Mengchao W, Han C, et al. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology. 2006;53:249–252.
   PubMed Web of Science ®Google Scholar
• Garaci E, Pica F, Serafino A, et al. Thymosin alpha1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci. 2012;1269:26–33.
   PubMed Web of Science ®Google Scholar